NO995894L - 2-(4-(4-(4,5-diklor-2-metylimidazol-1-yl)butyl)-1- piperazinyl)-5-fluorpyrimidin, fremstilling og terapeutisk anvendelse - Google Patents

2-(4-(4-(4,5-diklor-2-metylimidazol-1-yl)butyl)-1- piperazinyl)-5-fluorpyrimidin, fremstilling og terapeutisk anvendelse

Info

Publication number
NO995894L
NO995894L NO995894A NO995894A NO995894L NO 995894 L NO995894 L NO 995894L NO 995894 A NO995894 A NO 995894A NO 995894 A NO995894 A NO 995894A NO 995894 L NO995894 L NO 995894L
Authority
NO
Norway
Prior art keywords
methylimidazol
fluoropyrimidine
piperazinyl
dichloro
butyl
Prior art date
Application number
NO995894A
Other languages
English (en)
Other versions
NO318757B1 (no
NO995894D0 (no
Inventor
Ramon Merce-Vidal
Jordi Frigola-Costanza
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of NO995894D0 publication Critical patent/NO995894D0/no
Publication of NO995894L publication Critical patent/NO995894L/no
Publication of NO318757B1 publication Critical patent/NO318757B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19995894A 1997-06-02 1999-12-01 2-{4-[4-(4,5-diklor-2-metylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluorpyrimidin, fremstilling og terapeutisk anvendelse NO318757B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9706738A FR2763950B1 (fr) 1997-06-02 1997-06-02 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique
PCT/EP1998/003190 WO1998055476A1 (fr) 1997-06-02 1998-05-28 2-{4-[4-(4,5-dichloro-2- methylimidazol-1-yl)butyl] -1-piperazinyl}-5-fluoropyrimidine, sa preparation et son utilisation therapeutique

Publications (3)

Publication Number Publication Date
NO995894D0 NO995894D0 (no) 1999-12-01
NO995894L true NO995894L (no) 2000-02-01
NO318757B1 NO318757B1 (no) 2005-05-02

Family

ID=9507480

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995894A NO318757B1 (no) 1997-06-02 1999-12-01 2-{4-[4-(4,5-diklor-2-metylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluorpyrimidin, fremstilling og terapeutisk anvendelse

Country Status (22)

Country Link
US (2) US6303608B1 (no)
EP (1) EP1007522B1 (no)
JP (1) JP4344890B2 (no)
KR (1) KR100556559B1 (no)
CN (1) CN1094491C (no)
AT (1) ATE228126T1 (no)
AU (1) AU732722B2 (no)
BR (1) BR9810240A (no)
CA (1) CA2292746A1 (no)
DE (1) DE69809564T2 (no)
DK (1) DK1007522T3 (no)
ES (1) ES2149691B1 (no)
FR (1) FR2763950B1 (no)
HU (1) HUP0002905A3 (no)
IL (1) IL133216A0 (no)
NO (1) NO318757B1 (no)
NZ (1) NZ501566A (no)
PL (1) PL190777B1 (no)
PT (1) PT1007522E (no)
RU (1) RU2191184C2 (no)
TR (1) TR199903001T2 (no)
WO (1) WO1998055476A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101152658B1 (ko) * 2009-04-30 2012-06-18 한국과학기술연구원 세로토닌 5-ｈｔ6 길항 활성 효과를 갖는 피페라진 화합물 함유 조성물
RU2660583C1 (ru) * 2017-08-15 2018-07-06 Общество С Ограниченной Ответственностью "Валента - Интеллект" Применение буспирона для лечения функционального головокружения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2642759B1 (fr) * 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
FR2672052B1 (fr) 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
FR2665161B1 (fr) * 1990-07-26 1992-11-27 Esteve Labor Dr Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments.
FR2673628B1 (fr) * 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
FR2712808B1 (fr) * 1993-11-25 1996-02-16 Esteve Labor Dr Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique .
FR2742052B1 (fr) * 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports

Also Published As

Publication number Publication date
KR100556559B1 (ko) 2006-03-06
IL133216A0 (en) 2001-03-19
CN1094491C (zh) 2002-11-20
US6303608B1 (en) 2001-10-16
PL337113A1 (en) 2000-07-31
BR9810240A (pt) 2000-09-05
ES2149691B1 (es) 2001-05-16
RU2191184C2 (ru) 2002-10-20
HUP0002905A3 (en) 2002-01-28
JP4344890B2 (ja) 2009-10-14
EP1007522B1 (fr) 2002-11-20
NO318757B1 (no) 2005-05-02
DE69809564T2 (de) 2003-07-10
DE69809564D1 (de) 2003-01-02
HUP0002905A2 (hu) 2001-06-28
KR20010013274A (ko) 2001-02-26
TR199903001T2 (xx) 2000-07-21
FR2763950A1 (fr) 1998-12-04
NO995894D0 (no) 1999-12-01
CA2292746A1 (fr) 1998-12-10
WO1998055476A1 (fr) 1998-12-10
US6346620B1 (en) 2002-02-12
DK1007522T3 (da) 2003-03-17
EP1007522A1 (fr) 2000-06-14
FR2763950B1 (fr) 2002-09-20
AU7917098A (en) 1998-12-21
CN1261888A (zh) 2000-08-02
NZ501566A (en) 2001-06-29
ATE228126T1 (de) 2002-12-15
PL190777B1 (pl) 2006-01-31
PT1007522E (pt) 2003-04-30
AU732722B2 (en) 2001-04-26
JP2002501539A (ja) 2002-01-15
ES2149691A1 (es) 2000-11-01

Similar Documents

Publication Publication Date Title
NO324230B1 (no) Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av bipolare forstyrrelser og mani
IL162979A (en) 4-[(4-methyl-4-oxido-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide, pharmaceutical compositions comprising it and use thereof for the preparation of medicaments for the treatment of a proliferative disorder
NO2015009I1 (no) Nintedanib, tautomere og salter derav, spesielt Nintedanib og fysiologiske akseptable salter derav, spesielt Nintedanib esilat; 3-Z-[l-(4-(N-((4-metylpiperazin-1-yl)-metylkarbonyl)-N-metylamino)- anilino)-1-fenylmetylen]-6-metoksykarbonyl-2-indolinon - Se blant annet kravene 1, 2, 5 (t) og 6 i basispatentet
NO20081304L (no) Form av 3-[(2{4-(heksyloksykarbonylamino-imino-metyl)-fenylamino]-metyl}-1-metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]propionsyreetylester for oral administrering.
ATE363282T1 (de) Zusammensetzung zur unterdrückung von magensäure
HUP9902808A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
DE69433802D1 (de) Therapeutisch wirksame linksdrehende und rechtsdrehende 1-((4-Chlorphenyl)phenylmethyl) Piperazine
EA200400881A1 (ru) Азаарилпиперазины
GEP20022763B (en) 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor
NO940274D0 (no) 2-(4-(-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler
NO995894D0 (no) 2-(4-(4-(4,5-diklor-2-metylimidazol-1-yl)butyl)-1-piperazinyl)-5-fluorpyrimidin, fremstilling og terapeutisk anvendelse
BR0009080A (pt) Método de tratamento da apnéia do sono
NZ334571A (en) Pharmaceutical composition comprising 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-acetic acid for treating diseases induced by respiratory syncytial virus
WO2003009835A3 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
NO20024291D0 (no) Ny anvendelse av (R)-(-)-2[5-(4-fluorfenyl)-3- pyridylmetylaminometyl]kroman og dets fysiologisk akseptablesalter
ATE294572T1 (de) Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten
DE60208192D1 (de) 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DK1353906T3 (da) Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf
NO20010984L (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etyl]-4-piperidinmetanol for behandling av sovnforstyrrelser
RU2369605C2 (ru) Производные диарилмочевины, применяемые для лечения зависимых от протеинкиназ болезней
SI1353906T1 (en) Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
MX9706133A (es) Uso de los derivados de 1-{4-[4-aril(o heteroaril)-1-piperazinil]-butil}-1h-azol para la preparacion de un medicamento destinado al tratamiento de lostrastornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application